Today: 27 February 2026
Subscribe
Browse Category

NYSE:JNJ 10 December 2025 - 22 December 2025

Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson shares closed at $206.37 on Friday, about 4% below their 52-week high. A Minnesota jury awarded $65.5 million in a talc cancer case against the company, which plans to appeal. The FDA granted a priority review voucher for J&J’s Tecvayli-Darzalex multiple myeloma regimen, speeding regulatory timelines. Trading may see sharper moves this week due to holiday liquidity.
22 December 2025
Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson closed Friday, Dec. 19, 2025, at about $206 per share, as investors weighed U.S. drug-pricing negotiations and new talc verdicts against product pipeline momentum. The company is set to meet with the White House after the holidays over possible participation in the TrumpRx drug-pricing initiative. Trading volume is expected to be thin during the Christmas-shortened week.
21 December 2025
··
Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

A Minnesota jury awarded $65.5 million to a plaintiff who said Johnson & Johnson’s talc products caused mesothelioma, with J&J vowing to appeal. JNJ shares last traded at $206.37, down 0.9% from the prior close and about 3.6% below their December 15 record. Over 67,000 plaintiffs are suing J&J over similar claims. The company declared a $1.30 quarterly dividend for Q4 2025.
20 December 2025
·
Johnson & Johnson Stock After Hours Dec. 19, 2025: JNJ Ticks Up After the Bell—Key News, Forecasts, and What to Watch Before the Next Open

Johnson & Johnson Stock After Hours Dec. 19, 2025: JNJ Ticks Up After the Bell—Key News, Forecasts, and What to Watch Before the Next Open

Johnson & Johnson shares rose 0.51% to $207.43 in after-hours trading Friday, after closing down 0.9% in the regular session. The move followed late news on Washington drug-pricing talks, analyst targets, and litigation. JNJ was not among nine firms signing new Trump administration drug-pricing deals but was named as a company in ongoing discussions. U.S. markets are closed Saturday; trading resumes Monday.
20 December 2025
·
Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson shares hovered near $208 intraday on December 19, 2025, as investors weighed new U.S. drug-pricing talks involving the company, recent FDA approvals, and ongoing talc litigation. Reuters reported J&J remains in negotiations with the White House over prescription drug pricing reforms. The FDA approved Rybrevant Faspro for subcutaneous use in EGFR-mutated NSCLC.
19 December 2025
·
Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson shares closed Thursday at $208.31, down 0.96%, then edged up to $208.65 after hours. The company announced FDA clearance expanding TRUFILL n‑BCA’s use for chronic subdural hematoma and FDA approval for RYBREVANT FASPRO as a subcutaneous lung cancer treatment. JNJ’s market cap stands near $502 billion.
19 December 2025
·
Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

Johnson & Johnson shares traded near $210 on December 17, 2025, after a sharp drop the previous day and renewed analyst attention. RBC raised its price target to $240, maintaining an Outperform rating. The stock remains close to 2025 highs, with analysts split on near-term upside. JNJ continues to offer a quarterly dividend of $1.30 per share, yielding around 2%.
17 December 2025
·
Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson shares fell about 1% to $211–$212 late Tuesday morning after hitting recent highs, following news that the FDA granted a National Priority Voucher for its Tecvayli and Darzalex combination therapy for multiple myeloma. The FDA highlighted strong Phase 3 results and rapid review plans. Investors await the company’s upcoming earnings update for further guidance.
16 December 2025
···
Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson shares closed up 1.22% at $214.17 Monday and traded higher after hours following news that the FDA awarded a national priority voucher for its Tecvayli-daratumumab combination in relapsed/refractory multiple myeloma. The voucher, tied to strong Phase 3 MajesTEC-3 results, allows for accelerated FDA review. U.S. stocks overall ended slightly lower ahead of key economic data releases.
16 December 2025
·
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Eli Lilly reported late-stage trial success for its obesity drug retatrutide, with patients losing 28.7% of body weight over 68 weeks. Pfizer re-entered the obesity drug market through a $150 million licensing deal with Yao Pharma. The FDA moved to accelerate review of Lilly’s oral GLP-1 pill, orforglipron, possibly advancing a decision to March. The Fed cut rates by 25 basis points and signaled new Treasury purchases.
14 December 2025
······
Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson shares closed at $211.58 on Dec. 12, 2025, up 4.9% for the week after an FDA approval for AKEEGA in prostate cancer and new multiple myeloma data. The stock outperformed the broader market despite renewed talc litigation risk. A Federal Reserve rate cut earlier in the week supported large healthcare stocks. JNJ traded as high as $212.27 intraday Friday.
13 December 2025
··
Johnson & Johnson (JNJ) Stock News Today, Forecasts and Analyst Targets (Dec. 12, 2025)

Johnson & Johnson (JNJ) Stock News Today, Forecasts and Analyst Targets (Dec. 12, 2025)

Johnson & Johnson shares traded at $210.50 as of 14:33 UTC Friday, near Thursday’s all-time high close of $210.01. Wells Fargo and Morgan Stanley raised their price targets to $230 and $197, respectively, following similar moves by RBC, Citigroup, and HSBC. The average analyst target now sits just above the current price, with consensus ratings holding at “overweight.”
12 December 2025
·
Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson stock hit a 52-week high of about $208 on December 11, 2025, lifting its market cap above $500 billion after a rally that outpaced the S&P 500. The surge followed strong oncology trial results, new drug approvals, and optimism about offsetting Stelara sales declines. Legal risks and pricing pressures remain. JNJ’s dividend yield stands near 2.5%.
11 December 2025
·
Johnson & Johnson (JNJ) Stock After the Bell on December 10, 2025 – And What to Watch Before the December 11 Open

Johnson & Johnson (JNJ) Stock After the Bell on December 10, 2025 – And What to Watch Before the December 11 Open

Johnson & Johnson closed at $206.54 on Dec. 10, up 3.3% and less than 1% below its record high, after strong multiple myeloma drug data. After-hours trading edged the stock to $206.90, but premarket indications early Dec. 11 showed a drop to $202.50 on light volume. Year-to-date, JNJ has gained nearly 40%. The company faces ongoing talc litigation and regulatory scrutiny.
11 December 2025
··
Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson shares rose nearly 2% to about $204 on December 10, 2025, after new Phase 3 data showed its Tecvayli and Darzalex combo cut the risk of multiple myeloma progression or death by 83%. The company has filed for FDA approval, while investors weigh growth in oncology against ongoing talc litigation. JNJ stock is up over 38% year to date, outpacing healthcare peers.
10 December 2025
···
Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Johnson & Johnson shares closed at $199.96 on December 9, down 0.8% after touching $205.54 intraday. After the bell, the company reported Phase 3 data showing its TECVAYLI® + DARZALEX FASPRO® combination cut multiple myeloma progression or death risk by 83%. JNJ paid a $1.30 quarterly dividend, marking 63 years of dividend growth. Analyst consensus sees modest upside, with targets near $203–207.
10 December 2025
···
1 … 4 5 6 7 8
Go toTop